Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey

Basit Öğe Kaydı
dc.authorscopusid57189367146en_US
dc.authorwosidABI-3906-2020en_US
dc.contributor.authorÖzturk, Savaş
dc.contributor.authorTurgutalp, Kenan
dc.contributor.authorArıcı, Mustafa
dc.contributor.authorOdabaş, Ali Rıza
dc.contributor.authorAltıparmak, Mehmet Rıza
dc.contributor.authorAydın, Zeki
dc.contributor.authorBakırdöğen, Serkan
dc.date.accessioned2025-02-05T08:45:37Z
dc.date.available2025-02-05T08:45:37Z
dc.date.issued2021en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground. Chronic kidney disease (CKD) and immunosuppression, such as in renal transplantation (RT), stand as one of the established potential risk factors for severe coronavirus disease 2019 (COVID-19). Case morbidity and mortality rates for any type of infection have always been much higher in CKD, haemodialysis (HD) and RT patients than in the general population. A large study comparing COVID-19 outcome in moderate to advanced CKD (Stages 3-5), HD and RT patients with a control group of patients is still lacking. Methods. We conducted a multicentre, retrospective, observational study, involving hospitalized adult patients with COVID-19 from 47 centres in Turkey. Patients with CKD Stages 3-5, chronic HD and RT were compared with patients who had COVID-19 but no kidney disease. Demographics, comorbidities, medications, laboratory tests, COVID-19 treatments and outcome [in-hospital mortality and combined in-hospital outcome mortality or admission to the intensive care unit (ICU)] were compared. Results. A total of 1210 patients were included [median age, 61 (quartile 1-quartile 3 48-71) years, female 551 (45.5%)] composed of four groups: Control (n = 450), HD (n = 390), RT (n = 81) and CKD (n = 289). The ICU admission rate was 266/ 1210 (22.0%). A total of 172/1210 (14.2%) patients died. The ICU admission and in-hospital mortality rates in the CKD group [114/289 (39.4%); 95% confidence interval (CI) 33.9-45.2; and 82/289 (28.4%); 95% CI 23.9-34.5)] were significantly higher than the other groups: HD = 99/390 (25.4%; 95% CI 21.3-29.9; P<0.001) and 63/390 (16.2%; 95% CI 13.0-20.4; P<0.001); RT = 17/81 (21.0%; 95% CI 13.2-30.8; P = 0.002) and 9/81 (11.1%; 95% CI 5.7-19.5; P = 0.001); and control = 36/450 (8.0%; 95% CI 5.8-10.8; P<0.001) and 18/450 (4%; 95% CI 2.5-6.2; P<0.001). Adjusted mortality and adjusted combined outcomes in CKD group and HD groups were significantly higher than the control group [hazard ratio (HR) (95% CI) CKD: 2.88 (1.52- 5.44); P = 0.001; 2.44 (1.35-4.40); P = 0.003; HD: 2.32 (1.21- 4.46); P = 0.011; 2.25 (1.23-4.12); P = 0.008), respectively], but these were not significantly different in the RT from in the control group [HR (95% CI) 1.89 (0.76-4.72); P = 0.169; 1.87 (0.81-4.28); P = 0.138, respectively]. Conclusions. Hospitalized COVID-19 patients with CKDs, including Stages 3-5 CKD, HD and RT, have significantly higher mortality than patients without kidney disease. Stages 3-5 CKD patients have an in-hospital mortality rate as much as HD patients, which may be in part because of similar age and comorbidity burden. We were unable to assess if RT patients were or were not at increased risk for in-hospital mortality because of the relatively small sample size of the RT patients in this study.en_US
dc.identifier.citationÖzturk, S., Turgutalp, K., Arıcı, M., Odabaş, A. R., Altıparmak, M. R., Aydın, Z., … Ates, K. (2021). Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrology Dialysis Transplantation, 35(12), 2083–2095. https://doi.org/10.1093/ndt/gfaa271en_US
dc.identifier.doi10.1093/ndt/gfaa271en_US
dc.identifier.endpage2095en_US
dc.identifier.issn0931-0509 / 1460-2385
dc.identifier.issue12en_US
dc.identifier.pmidPMID: 33275763en_US
dc.identifier.scopus2-s2.0-85097310948en_US
dc.identifier.scopusqualityQ1
dc.identifier.startpage2083en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfaa271
dc.identifier.urihttps://hdl.handle.net/20.500.12428/29540
dc.identifier.volume35en_US
dc.identifier.wosWOS:000607840600010en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBakırdöğen, Serkan
dc.institutionauthorid0000-0002-3448-0490
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subjectCOVID-19en_US
dc.subjectHaemodialysisen_US
dc.subjectKidney diseaseen_US
dc.subjectMortalityen_US
dc.subjectRenal transplantationen_US
dc.titleMortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkeyen_US
dc.typearticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Serkan Bakirdogen_Makale.pdf
Boyut:
818.88 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Araştırma Makalesi
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.21 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu